Skip to content

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Incyte logo
IncyteINCY
3.3×+0.1×
Gilead Sciences logo
Gilead SciencesGILD
7.4×+0.1×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×

Other financials

Income statement

See full
Revenue$11.5B+2.6%
Gross profit$8.1B-1.2%
Net income$2.7B+9.0%
EPS (diluted)$1.31+9.2%

Balance sheet

See full
Cash & equivalents$9.6B-12.0%
Total debt$44.7B-10.5%
Total equity$20.1B+15.4%
Total assets$86.5B-6.4%

Cash flow

See full
Operating cash flow$1.1B-43.5%
CapEx$347.0M+33.5%
Free cash flow$757.0M-55.3%

Valuation

See full
Market cap$112.89B-0.2%
Enterprise value$147.97B-2.6%
P/E15.5×-5.6×
P/S2.3×0.0×

Profitability

See full
Gross margin70.5%0.0pp
Net margin15%+3.8pp

Returns & leverage

See full
Return on equity38.8%+7.3pp
Debt / equity2.2×-0.6×
Current ratio1.4×+0.1×

Where this comes from

Calculated from Bristol-Myers Squibb’s reported figures.

Based on the most recent quarter.

The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bristol-Myers Squibb's price / book?
Bristol-Myers Squibb (BMY) reported price / book of 6.2× in Q1 2026.
How has Bristol-Myers Squibb's price / book changed year-over-year?
Bristol-Myers Squibb's price / book decreased by 13.5% year-over-year, from 7.1× to 6.2×.
What is the long-term trend for Bristol-Myers Squibb's price / book?
Over 4 years (2021 to 2025), Bristol-Myers Squibb's price / book has grown at a 11.6% compound annual growth rate (CAGR), from 15.1× to 23.5×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.